ready, set, grow

These are the 5 fastest-growing companies in Houston, according to a recent report

Inc. magazine has identified the fastest-growing companies in Houston. Nick Bee/Pexels

Bellaire-based startup Instafuel is pumping up its revenue in a big way.

Among the 250 fastest-growing companies in Texas identified by Inc. magazine, Instafuel tops the group of businesses based in the Houston metro area and ranks fifth statewide. Houston-based companies make up 68 of the state's fast-growing companies — eight Houston companies make up the top 25 list.

Instafuel, whose official corporate name is Fuel Husky LLC, provides mobile refueling services to B2B clients. The Inc. ranking, released March 13, shows Instafuel posted revenue growth of 1,353 percent from 2016 to 2018.

According to a November 2019 article published by CSP magazine, Instafuel has expanded to 30 trucks that have dispensed nearly 10 million gallons of fuel to more than 150 B2B clients in major Texas metro markets like Houston, Dallas-Fort Worth, and Austin. CSP covers the convenience and petroleum retailing industry.

"We've been bootstrapping … in stealth mode for the last four years, just trying to grow this business one [client] by one, trying to truly understand what it means to be a mobile refueler, or what we call a compact mobile refueler, and trying to target and understand the business model for small- to medium-sized business fleets," Nour Baki, vice president and co-founder of Instafuel, told the magazine.

Ranked second in the Houston area and sixth statewide by Inc. is Spring-based Bellatorum Resources LLC, whose revenue shot up 1,261 percent from 2016 to 2018. Bellatorum, a veteran-owned and veteran-operated investment company, specializes in mineral rights and oil royalty acquisitions.

"I think our work ethic and customer service is what makes us different from our competitors," Chris Bentley, president and CEO of Bellatorum Resources, told the Oil & Gas Council in July 2018.

"Based on the feedback I consistently receive from mineral owners, they tell me that many of our competitors fail to return phone calls and emails, and sometimes even fail to treat them with common courtesy and respect during their business dealings," Bentley added. "We believe in putting the mineral owner first, which always pays off for us."

At No. 3 in the Houston area and No. 8 statewide is Houston-based Sarvicus LLC. Sarvicus, an IT services and utilities provider, grew revenue by 1,048 percent from 2016 to 2018.

"Whether it's a process, piece of equipment, or a tool, we try to optimize its efficiency. When we are successful, that often translates to benefits for our customers," Sarvicus co-founder and CEO Marc Packard told CIOReview magazine.

Houston-based SIA Solutions LLC appears at No. 4 among Houston-area companies and No. 9 among Texas companies. From 2016 to 2018, revenue at the professional services engineering and consulting firm soared 1,030 percent.

"Because of our client-first philosophy, we're willing to take on tough challenges and deliver. It's in our culture. It's natural to us," CEO Srini Neralla told the McFerrin Center for Entrepreneurship at Texas A&M University's Mays Business School in November 2019. We put together strong teams comprising of firms our size or larger, including universities, in order to deliver what our clients want."

With a 2016-18 growth rate of 824 percent, Houston-based Zahroof Valves Inc. nails down the No. 5 spot among Houston-area companies and No. 14 among Texas companies. Zahroof Values makes and markets specialized valves for reciprocating gas compressors. Its investors include Saudi Aramco Energy Ventures LLC, the investment arm of oil giant Saudi Aramco.

In an August 2019 release, Zahroof Valves CEO Tony Gioffredi said: "Our commitment to driving positive change [in] the oil and gas industry is shown through our innovative products … ."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News